A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (December 2021) (Learn how and when to remove this template message)
Sintilimab
Monoclonal antibody
Type?
Clinical data
Other namesAnti-PD-1 monoclonal antibody IBI308[1]
Identifiers
CAS Number
UNII
KEGG

Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease,[2] and has been approved in China.[3]

It is a fully human IgG4 monoclonal antibody[4] that binds to programmed cell death protein 1.[5]

It was jointly developed by Innovent Biologics[6] and Eli Lilly.[7]

Medical uses

Sintilimab is medication that is indicated for the treatment of relapsed or refractory classical Hodgkin's lymphoma[8] after failure of at least second-line systemic chemotherapy.[5]

Side effects

Common side effects include fever, thyroid dysfunction, elevation of liver enzymes, and lung inflammation.[9]

Research

Currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors.[10] In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published.[8]

References

  1. ^ "anti-PD-1 monoclonal antibody IBI308". NCI Drug Dictionary. National Cancer Institute. 2011-02-02.
  2. ^ "Antibody Drug Conjugates Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026". Reuters. October 24, 2018.
  3. ^ "NMPA Approves Tyvyt For Hodgkin's lymphoma Read". Asian Scientist Magazine. January 9, 2019.
  4. ^ Ying K, Xu N, Jiang H, Liu Y, Zhou H, Wang S (2018). "OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer". Journal of Thoracic Oncology. 13 (12): S1047. doi:10.1016/j.jtho.2018.10.018. Retrieved Dec 1, 2018.
  5. ^ a b Hoy SM (February 2019). "Sintilimab: First Global Approval". Drugs. 79 (3): 341–346. doi:10.1007/s40265-019-1066-z. PMID 30742278. S2CID 59945274.
  6. ^ "Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company". SEC.gov. December 20, 2018.
  7. ^ "Sintilimab - Eli Lilly/Innovent Biologics". Adis Insight. Springer Nature Switzerland AG. 28 March 2019.
  8. ^ a b Ansell SM (January 2019). "Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma". The Lancet. Haematology. 6 (1): e2–e3. doi:10.1016/S2352-3026(18)30210-2. PMID 30612711. S2CID 58561198.
  9. ^ A first-in-human phase 1a trial of sintilimab (IBI308). 2018 ASCO Annual Meeting. American Society of Clinical Oncology. 12 October 2019.
  10. ^ Innovent Biologics, Inc. "Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection)". PR NewsWire (Press release). Retrieved Feb 22, 2019.
Categories